Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-11-14 6:23 pm Purchase | 13G | Avalo Therapeutics Inc. AVTX | ORBIMED ADVISORS LLC | 967,000 9.900% | 967,000 (New Position) | View |
| 2024-11-14 12:05 pm Sale | 13G | Avalo Therapeutics Inc. AVTX | Allostery Investments LP | 55,840 0.500% | -22,415 (-28.64%) | View |
| 2024-11-07 5:00 pm Purchase | 13G | Avalo Therapeutics Inc. AVTX | Crutcher Patrick J | 549,467 5.600% | 438,616 (+395.68%) | View |
| 2024-10-07 8:06 pm Purchase | 13G | Avalo Therapeutics Inc. AVTX | Ikarian Capital LLC | 970,359 10.020% | 970,359 (New Position) | View |
| 2024-08-23 4:34 pm Purchase | 13G | Avalo Therapeutics Inc. AVTX | BIOTECHNOLOGY VALUE FUND L P | 967,299 9.990% | 967,299 (New Position) | View |
| 2024-08-23 4:16 pm Purchase | 13G | Avalo Therapeutics Inc. AVTX | RA CAPITAL MANAGEMENT L.P. | 967,299 9.990% | 967,299 (New Position) | View |
| 2024-08-23 4:05 pm Purchase | 13G | Avalo Therapeutics Inc. AVTX | Crutcher Patrick J | 110,851 9.900% | 110,851 (New Position) | View |
| 2024-05-13 12:38 pm Purchase | 13G | Avalo Therapeutics Inc. AVTX | Allostery Investments LP | 78,255 7.600% | 78,255 (New Position) | View |
| 2024-04-23 2:59 pm Purchase | 13G | Avalo Therapeutics Inc. AVTX | Emerald Bioventures LLC | 58,346 5.600% | 58,346 (New Position) | View |
| 2024-04-05 4:00 pm Purchase | 13G | Avalo Therapeutics Inc. AVTX | Deep Track Capital LP | 114,775 9.990% | 114,775 (New Position) | View |
| 2024-02-14 9:13 pm Unchanged | 13G | Avalo Therapeutics Inc. AVTX | Venrock Healthcare Capital Partners III L.P. | 0 0.000% | 0 (Unchanged) | View |
| 2024-02-14 4:51 pm Sale | 13G | Avalo Therapeutics Inc. AVTX | Nantahala Capital Management LLC | 42,100 4.900% | -612,574 (-93.57%) | View |
| 2024-02-14 4:36 pm Purchase | 13G | Avalo Therapeutics Inc. AVTX | GREAT POINT PARTNERS LLC | 2,085 0.260% | 2,085 (New Position) | View |
| 2024-02-14 10:02 am Purchase | 13G | Avalo Therapeutics Inc. AVTX | Point72 Asset Management L.P. | 2,500 0.300% | 2,500 (New Position) | View |
| 2023-06-29 08:22 am Sale | 13G | Avalo Therapeutics Inc. AVTX | Caissa Capital Management ltd. | 0 0.000% | -1,475,000 (Position Closed) | View |
| 2023-06-27 6:02 pm Sale | 13D | Avalo Therapeutics Inc. AVTX | ARMISTICE CAPITAL LLC | 623,220 4.990% | -4,159,483 (-86.97%) | View |
| 2023-04-19 4:38 pm Purchase | 13G | Avalo Therapeutics Inc. AVTX | Caissa Capital Management ltd. | 1,475,000 11.190% | 81,329 (+5.84%) | View |
| 2023-02-17 4:05 pm Purchase | 13G | Avalo Therapeutics Inc. AVTX | Venrock Healthcare Capital Partners III L.P. | 1,352,285 9.990% | 1,352,285 (New Position) | View |
| 2023-02-14 4:58 pm Sale | 13G | Avalo Therapeutics Inc. AVTX | Nantahala Capital Management LLC | 654,674 7.000% | -7,859,243 (-92.31%) | View |
| 2023-02-14 4:22 pm Purchase | 13G | Avalo Therapeutics Inc. AVTX | Point72 Asset Management L.P. | 500,737 5.300% | 500,737 (New Position) | View |